Researchers Identify Common Side Effects of Three COVID-19 Vaccines – .

0
17
Researchers Identify Common Side Effects of Three COVID-19 Vaccines – .


COVID-19 vaccines remain the best tool in the pandemic toolkit against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). But they are not perfect; there have been reports of mild to severe side effects after vaccination. A new study by researchers at Lampe & Company GmbH & Co. KG compared the severity of adverse events from each vaccine against the coronavirus.

Compared to infection with COVID-19 and the risk of long-lasting COVID, the side effects of the vaccine are temporary and are unlikely to cause hospitalization. But their results suggest that each vaccine carries a common risk of fatigue, headaches, and muscle weakness. In addition, people aged 18 to 55 were more likely to experience side effects from the vaccine than people over 55.

Understanding the side effects of each vaccine can help shape the message surrounding vaccine safety, help plan future vaccination campaigns, and inform the public of their decision to get vaccinated.

“The multidimensional assessment of the published vaccine data presented here can serve as the basis for a public awareness campaign to combat vaccine reluctance by identifying and explaining phenomena that the public perceives intuitively,” the researchers concluded.

The study “An objective systematic comparison of the most common adverse events of COVID-19 vaccines” is published as a pre-publication on the medRxiv* server.

How they did

Researchers performed a systemic search of 10 journal articles and 2 regulatory documents available from May 31, 2021, which looked for adverse events after COVID-19 vaccination. Items used by the U.S. Food & Drug Administration and the European Medical Agency to approve vaccines were also considered.

The vaccines targeted for this study were the Pfizer-BioNTech vaccine, the Moderna vaccine, and the AstraZeneca / Oxford vaccine.

In total, there were 66 different study arms with relevant vaccine safety information.

Most common systemic adverse events occurring after the first and second doses of SARS-CoV-2 vaccines. The highest frequencies for each adverse event occurring with each vaccine are shown. For BioNTech, only young / middle-aged (18-65 years) subjects are included; no data was available for the entire population. Sources: AstraZeneca (AZ): EMA assessment report (2021); BioNTech (BNT): Polack et al. (2020); Moderna (MOD): Baden et al. (2020).

COVID-19 vaccines have a good safety profile with mild side effects

The three COVID-19 vaccines shared the following mild side effects: fatigue, headache, and muscle weakness. But overall, all were well tolerated and temporary.

Side effects were most reported after the first dose of AstraZeneca vaccine. In contrast, the two mRNA vaccines showed the highest number of reports of adverse events after the second dose.

Overall frequency of systemic adverse events by age group observed with anti-SARS-CoV-2 vaccines. The highest frequencies observed for each adverse event are presented here, regardless of dose (first or second). * The maximum age for middle-aged subjects and the minimum age for senior subjects vary from 55 to 65 years. Sources: AstraZeneca (AZ): Ramasamy et al. (2020); BioNTech (BNT): Polack et al. (2020); Moderna (MOD): Baden et al. (2020)

The number of adverse events from the first dose of AstraZeneca corresponded to the number of adverse events observed with the second dose of mRNA.

Vice versa, the number of adverse events from the second dose of AstraZeneca was similar to the number of adverse events from the first doses of mRNA.

“Overall, regardless of dose, the frequency of each AE was very similar from vaccine to vaccine and did not show a tendency for one vaccine over another, regardless of platform. form used (non-replicating viral vector or mRNA), ”the research team wrote.

People aged 18 to 55 reported more side effects from the vaccine than people over 55. This observation was observed among the three vaccines against the coronavirus.

Because the risk of blood clots and thrombosis is rare after vaccination, researchers have found no report in any of the clinical trials.

*Important Notice

medRxiv publishes preliminary scientific reports that are not peer reviewed and, therefore, should not be considered conclusive, guide clinical practice / health-related behavior, or treated as established information.

LEAVE A REPLY

Please enter your comment!
Please enter your name here